Showing results (241-250 of 287) with videos related to

Sort By:
Pageof 29
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2013
Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessmentStaley A Brod, Larry A Kramer, Alan M Cohen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, C C Ford, et al.
Neurology|September 6, 2019
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosisFrederik Barkhof, Ludwig Kappos, Jerry S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 8, 2022
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMSDouglas L Arnold, Till Sprenger, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.
The Lancet. Neurology|November 23, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce A C Cree, Gary Cutter, Jerry S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 4, 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-studyXavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, et al.
The Lancet. Neurology|November 1, 2020
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S Wolinsky, Douglas L Arnold, Bruno Brochet, et al.
Multiple Sclerosis and Related Disorders|September 10, 2020
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension studyAaron E Miller, Tomas P Olsson, Jerry S Wolinsky, et al.
Neurology|February 12, 2016
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO studyPaul O'Connor, Giancarlo Comi, Mark S Freedman, et al.
Pageof 29